Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
HelloAva is an innovative new platform that uses AI technology to provide a person...
HelloAva is an innovative new platform that use...
CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investmen...
CareTrust REIT, Inc. is a self-administered, pu...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Admedus Limited is a bio medical group. The Group commercializes tissue engineerin...
Admedus Limited is a bio medical group. The Gro...
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Join the National Investor Network and get the latest information with your interests in mind.